Cargando…

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Takayuki, Yamada, Tadaaki, Tanimura, Keiko, Nakano, Takayuki, Ishida, Masaki, Tachibana, Yusuke, Shiotsu, Shinsuke, Horiuchi, Shigeto, Hibino, Makoto, Okada, Asuka, Chihara, Yusuke, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699991/
https://www.ncbi.nlm.nih.gov/pubmed/34943412
http://dx.doi.org/10.3390/diagnostics11122170
_version_ 1784620648056750080
author Takeda, Takayuki
Yamada, Tadaaki
Tanimura, Keiko
Nakano, Takayuki
Ishida, Masaki
Tachibana, Yusuke
Shiotsu, Shinsuke
Horiuchi, Shigeto
Hibino, Makoto
Okada, Asuka
Chihara, Yusuke
Takayama, Koichi
author_facet Takeda, Takayuki
Yamada, Tadaaki
Tanimura, Keiko
Nakano, Takayuki
Ishida, Masaki
Tachibana, Yusuke
Shiotsu, Shinsuke
Horiuchi, Shigeto
Hibino, Makoto
Okada, Asuka
Chihara, Yusuke
Takayama, Koichi
author_sort Takeda, Takayuki
collection PubMed
description The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in patients with several cancers, their usefulness in targeted therapies is scarce, and their significance has never been reported in patients receiving first-line treatment with alectinib. Meanwhile, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) has been investigated during crizotinib treatment. This multicenter retrospective study evaluated 42 consecutive Japanese patients with ALK-positive NSCLC who received first-line treatment with alectinib. Immunological and nutritional markers were evaluated at baseline and 3 weeks after alectinib introduction, and their significance in predicting progression-free survival (PFS) was explored. PFS duration was significantly associated with baseline PLR (hazard ratio (HR): 2.49, p = 0.0473), systemic immune-inflammation index (SII; HR: 2.65, p = 0.0337), prognostic nutrition index (PNI; HR: 4.15, p = 0.00185), and the 3-week values for SII (HR: 2.85, p = 0.0473) and PNI (HR: 3.04, p = 0.0125). Immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib. Since PLR and SII consist of platelet counts, platelet count could be an important constituent of these markers.
format Online
Article
Text
id pubmed-8699991
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86999912021-12-24 Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib Takeda, Takayuki Yamada, Tadaaki Tanimura, Keiko Nakano, Takayuki Ishida, Masaki Tachibana, Yusuke Shiotsu, Shinsuke Horiuchi, Shigeto Hibino, Makoto Okada, Asuka Chihara, Yusuke Takayama, Koichi Diagnostics (Basel) Article The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in patients with several cancers, their usefulness in targeted therapies is scarce, and their significance has never been reported in patients receiving first-line treatment with alectinib. Meanwhile, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) has been investigated during crizotinib treatment. This multicenter retrospective study evaluated 42 consecutive Japanese patients with ALK-positive NSCLC who received first-line treatment with alectinib. Immunological and nutritional markers were evaluated at baseline and 3 weeks after alectinib introduction, and their significance in predicting progression-free survival (PFS) was explored. PFS duration was significantly associated with baseline PLR (hazard ratio (HR): 2.49, p = 0.0473), systemic immune-inflammation index (SII; HR: 2.65, p = 0.0337), prognostic nutrition index (PNI; HR: 4.15, p = 0.00185), and the 3-week values for SII (HR: 2.85, p = 0.0473) and PNI (HR: 3.04, p = 0.0125). Immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib. Since PLR and SII consist of platelet counts, platelet count could be an important constituent of these markers. MDPI 2021-11-23 /pmc/articles/PMC8699991/ /pubmed/34943412 http://dx.doi.org/10.3390/diagnostics11122170 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Takeda, Takayuki
Yamada, Tadaaki
Tanimura, Keiko
Nakano, Takayuki
Ishida, Masaki
Tachibana, Yusuke
Shiotsu, Shinsuke
Horiuchi, Shigeto
Hibino, Makoto
Okada, Asuka
Chihara, Yusuke
Takayama, Koichi
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title_full Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title_fullStr Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title_full_unstemmed Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title_short Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
title_sort prognostic markers of survival among japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699991/
https://www.ncbi.nlm.nih.gov/pubmed/34943412
http://dx.doi.org/10.3390/diagnostics11122170
work_keys_str_mv AT takedatakayuki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT yamadatadaaki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT tanimurakeiko prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT nakanotakayuki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT ishidamasaki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT tachibanayusuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT shiotsushinsuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT horiuchishigeto prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT hibinomakoto prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT okadaasuka prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT chiharayusuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib
AT takayamakoichi prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib